Gilead C-Level Executives Sell Shares Under 10b5-1 Plan

Two C-level executives at Gilead Sciences, Inc. (NASDAQ: GILD)—the Chief Financial Officer and the Chief Commercial & Corporate Affairs Officer—each sold 3,000 shares of the company’s common stock on April 15, and another executive, Mercier, disposed of 3,000 shares on March 16. All three transactions were made under pre-arranged Rule 10b5-1 trading plans. Each sale generated proceeds of approximately $420,000–$430,000 (about KRW 600 million), and the two officers still hold roughly 170,000 and 130,000 shares respectively, preserving a significant portion of their stakes.

On April 7, Gilead agreed to acquire German antibody-drug conjugate developer Tubulis for up to $5 billion (approximately KRW 7 trillion). Earlier in February, the company announced plans to buy U.S. CAR-T firm Ascelax for about $7.8 billion (around KRW 11 trillion), reinforcing its strategy to expand its oncology portfolio. More recently, Gilead’s guidance for 2026 financial results came in at the lower end of market expectations, triggering a roughly 2% short-term pullback in its share price and heightened volatility.

Headquartered in Foster City, California, Gilead Sciences is a global biopharmaceutical company that grew through antiviral therapies for HIV and hepatitis B and C, as well as the COVID-19 treatment Veklury. Today, it is simultaneously advancing its HIV treatment and prevention offerings alongside its oncology lineup. The company’s mid- to long-term goal is to launch more than 10 innovative therapies by 2030, led by a lenacapavir-based HIV prevention agent and oncology candidates such as Trodelvy.